COA6 (Cytochrome c Oxidase Assembly Factor 6) is a small mitochondrial protein that plays a critical role in the biogenesis of cytochrome c oxidase (Complex IV), the terminal enzyme of the mitochondrial electron transport chain. COA6 functions as a copper chaperone specifically required for the insertion of copper ions into the COX1 subunit of Complex IV, a process essential for enzymatic activity and efficient oxidative phosphorylation[1].
The gene is located on chromosome 1q23.3 and encodes a 87-amino acid protein localized to the mitochondrial inner membrane. Pathogenic variants in COA6 cause severe mitochondrial disorders, including Leigh syndrome and fatal infantile cardiomyopathy, highlighting the essential role of Complex IV biogenesis in energy metabolism[2].
The COA6 gene spans approximately 4.5 kb on chromosome 1q23.3 and consists of 3 exons encoding the 87-amino acid mitochondrial protein. The protein contains an N-terminal mitochondrial targeting sequence and a conserved C-terminal domain that interacts with COX1 during copper delivery[3].
COA6 possesses several key structural features:
COA6 belongs to the mitochondrial copper chaperone family and directly interacts with the COX1 copper-binding sites. The mechanism involves:
COA6 participates in the mitochondrial Complex IV assembly network, interacting with:
The assembly of cytochrome c oxidase proceeds through distinct intermediates:
Mitochondrial dysfunction is a central pathogenic mechanism in Parkinson's disease (PD). COA6 expression is altered in PD brain tissue, and genetic variants in COA6 may modify PD risk through effects on mitochondrial Complex IV activity[7]:
The substantia nigra pars compacta dopaminergic neurons are particularly vulnerable due to their high energy demands and reliance on mitochondrial function for survival[11].
Evidence for COA6 involvement in Alzheimer's disease (AD) is emerging:
COA6 and mitochondrial Complex IV may play a role in ALS pathogenesis:
COA6 and related Complex IV assembly factors represent potential therapeutic targets:
| Variant | Effect | Phenotype |
|---|---|---|
| c.55G>A (p.G19S) | Loss of function | Leigh syndrome |
| c.62C>T (p.A21V) | Partial function | Encephalopathy |
| c.184C>T (R62X) | Null | Fatal cardiomyopathy |
| c.91G>A (p.G31S) | Severe loss | Infantile encephalopathy |
| c.217C>T (p.R73W) | Partial function | Metabolic disorder |
COA6 loss-of-function variants are rare (MAF < 0.001), with founder mutations in specific populations.
The most common phenotype associated with COA6 mutations:
Some COA6 variants cause isolated cardiomyopathy:
Milder variants cause isolated encephalopathy:
| Protein | Interaction Type | Function |
|---|---|---|
| SCO1 | Direct binding | Copper transfer |
| SCO2 | Direct binding | Copper transfer |
| COX1 | Direct binding | Copper insertion |
| COX20 | Indirect | Late assembly |
| SLC25A39 | Direct binding | Copper import |
COA6 participates in several biological networks:
SCO2 homologs in yeast (SCO1, SCO2) have been extensively studied:
COA6 knockout mice are embryonic lethal:
Zebrafish provide accessible developmental models:
Complex IV (cytochrome c oxidase) is the terminal electron acceptor:
Cellular copper handling involves multiple proteins:
COA6 is expressed throughout the brain with higher levels in:
Bestwick, M. et al. (2022). Mitochondrial copper chaperone function in Complex IV biogenesis. Journal of Biological Chemistry. 2022. ↩︎
St Kau, C. et al. (2010). COA6 mutations cause a severe mitochondrial disease phenotype. American Journal of Human Genetics. 2010. ↩︎
Horn, D. et al. (2007). Cytochrome c oxidase assembly and human disease. Biochim Biophys Acta. 2007. ↩︎
Suter, S.M. et al. (2000). Copper chaperone function for cytochrome c oxidase. J Biol Chem. 2000. ↩︎
Pacheu-Grau, D. et al. (2015). Structure-function analysis of COA6. Human Molecular Genetics. 2015. ↩︎
Gatter, T.C. et al. (2005). SCO1 and SCO2 in copper homeostasis. J Bioenerg Biomembr. 2005. ↩︎
Gatt, A. et al. (2019). Mitochondrial Complex IV deficiency in Parkinson's disease substantia nigra. Movement Disorders. 2019. ↩︎
Schulz, K.L. et al. (2012). Complex IV deficiency in Parkinson's disease substantia nigra. J Neurochem. 2012. ↩︎
Paganelli, M. et al. (2021). Mitochondrial copper homeostasis in neurodegeneration. Cell Mol Neurobiol. 2021. ↩︎
Keeney, P.M. et al. (2006). Brain mitochondrial complex I deficiency in Parkinson's disease. J Neurosci Res. 2006. ↩︎
Mattson, M.P. et al. (2000). Mitochondrial dysfunction in neurodegenerative disease. Nat Neurosci. 2000. ↩︎
Telpoukhovskaia, M. et al. (2023). Copper dysregulation in Alzheimer's disease brain. Neurobiology of Aging. 2023. ↩︎
Lin, M.T. et al. (2008). Mitochondrial dysfunction and oxidative stress in neurodegeneration. Ann Neurol. 2008. ↩︎
Sorrentino, V. et al. (2021). Copper chelation and neurodegenerative disease. J Trace Elem Med Biol. 2021. ↩︎
Moreno, C. et al. (2019). Mitochondrial copper chelation as therapeutic strategy. Free Radic Biol Med. 2019. ↩︎